Australian company Immutep has announced positive efficacy and safety results from the TACTI-003 Phase 2b trial evaluating its eftilagimod alpha in combination with MSD’s KEYTRUDA. …
Immutep says its candidate in combination with Keytruda delivered positive efficacy and safety profile
September 16, 2024 Latest NewsAustralian Biotech
Latest Video
New Stories
-
Australia 'is not an island' on pricing and we cannot be so arrogant to expect free product
August 13, 2026 - - Latest News -
Survey exposes deep gaps in neurological care across Australia
August 13, 2026 - - Latest News -
US childhood vaccine move away from combinations contrasts with Australia’s national schedule
August 12, 2026 - - Latest News -
Former minister joins DBG Health board as company broadens healthcare ambition
August 12, 2026 - - Latest News -
A sage appointment that puts DBG Health another step closer to a serious understanding of decision-making
August 12, 2026 - - Latest News -
Patients welcome the timely PBS listing of rare cancer therapy
August 12, 2026 - - Latest News -
How education exposes the moral and ethical limits of our health decision-making
August 11, 2026 - - Latest News